These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21498956)

  • 1. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine.
    Ago Y; Koda K; Takuma K; Matsuda T
    J Pharmacol Sci; 2011; 116(1):6-17. PubMed ID: 21498956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological profiles of galantamine: the involvement of muscarinic receptor].
    Matsuda T; Ago Y; Takuma K
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):1-8. PubMed ID: 22568120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotinic cholinergic modulation: galantamine as a prototype.
    Woodruff-Pak DS; Lander C; Geerts H
    CNS Drug Rev; 2002; 8(4):405-26. PubMed ID: 12481195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the pharmacology of galantamine.
    Villarroya M; García AG; Marco-Contelles J; López MG
    Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Alzheimer drugs (galantamine).
    Raskind MA
    Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists.
    Friedman JI
    Psychopharmacology (Berl); 2004 Jun; 174(1):45-53. PubMed ID: 15205878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating disorders across the lifespan by modulating cholinergic signaling with galantamine.
    Metz CN; Pavlov VA
    J Neurochem; 2021 Sep; 158(6):1359-1380. PubMed ID: 33219523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation.
    Koda K; Ago Y; Yano K; Nishimura M; Kobayashi H; Fukada A; Takuma K; Matsuda T
    Br J Pharmacol; 2011 Feb; 162(3):763-72. PubMed ID: 20958289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology.
    Coyle JT; Geerts H; Sorra K; Amatniek J
    J Alzheimers Dis; 2007 Jul; 11(4):491-507. PubMed ID: 17656829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice.
    Wilkinson DS; Gould TJ
    Behav Brain Res; 2011 Sep; 223(1):53-7. PubMed ID: 21514327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Galantamine activates muscle-type nicotinic acetylcholine receptors without binding to the acetylcholine-binding site.
    Akk G; Steinbach JH
    J Neurosci; 2005 Feb; 25(8):1992-2001. PubMed ID: 15728839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galantamine facilitates acquisition of hippocampus-dependent trace eyeblink conditioning in aged rabbits.
    Weible AP; Oh MM; Lee G; Disterhoft JF
    Learn Mem; 2004; 11(1):108-15. PubMed ID: 14747524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems.
    Noda Y; Mouri A; Ando Y; Waki Y; Yamada SN; Yoshimi A; Yamada K; Ozaki N; Wang D; Nabeshima T
    Int J Neuropsychopharmacol; 2010 Nov; 13(10):1343-54. PubMed ID: 20219155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor.
    Wadenberg ML; Fjällström AK; Federley M; Persson P; Stenqvist P
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):644-54. PubMed ID: 20701827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galantamine: use in Alzheimer's disease and related disorders.
    Bullock R
    Expert Rev Neurother; 2004 Mar; 4(2):153-63. PubMed ID: 15853556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Beneficial effect of galantamine on sensory information-processing deficits].
    Ago Y
    Yakugaku Zasshi; 2010 Oct; 130(10):1305-10. PubMed ID: 20930482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.
    Santos MD; Alkondon M; Pereira EF; Aracava Y; Eisenberg HM; Maelicke A; Albuquerque EX
    Mol Pharmacol; 2002 May; 61(5):1222-34. PubMed ID: 11961141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nicotinic Receptor, galantamine and Alzheimer disease].
    Arroyo G; Aldea M; Fuentealba J; García AG
    Rev Neurol; 2002 Jun 1-15; 34(11):1057-65. PubMed ID: 12134305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Galantamine: a novel cholinergic agent for Alzheimer's disease].
    Olazarán J; García G
    Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.